Drug Profile
BP C2
Alternative Names: BP-C2Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Meabco
- Class Antineoplastics; Heavy metals; Polyphenols; Radioprotectives
- Mechanism of Action Free radical scavengers; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Chemotherapy-induced damage
- Preclinical Acute radiation syndrome
- No development reported Radiation injuries